Regular proton pump inhibitor use and incident dementia: population-based cohort study

Abstract Background To examine the association between regular use of proton pump inhibitors and the risk of incident dementia, including dementia subtypes, and whether the association differs between APOE genotypes. Methods Based on a prospective analysis of data from the UK Biobank, 501,002 indivi...

Full description

Bibliographic Details
Main Authors: Peidong Zhang, Zhihao Li, Peiliang Chen, Ao Zhang, Yu Zeng, Xiru Zhang, Qingmei Huang, Dan Liu, Songtao Qi, Chen Mao
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12916-022-02478-y
_version_ 1798004318331207680
author Peidong Zhang
Zhihao Li
Peiliang Chen
Ao Zhang
Yu Zeng
Xiru Zhang
Qingmei Huang
Dan Liu
Songtao Qi
Chen Mao
author_facet Peidong Zhang
Zhihao Li
Peiliang Chen
Ao Zhang
Yu Zeng
Xiru Zhang
Qingmei Huang
Dan Liu
Songtao Qi
Chen Mao
author_sort Peidong Zhang
collection DOAJ
description Abstract Background To examine the association between regular use of proton pump inhibitors and the risk of incident dementia, including dementia subtypes, and whether the association differs between APOE genotypes. Methods Based on a prospective analysis of data from the UK Biobank, 501,002 individuals (female, 54.4%) aged between 40 and 70 years, who had no prevalent dementia at baseline, were enrolled between 2006 and 2010 and followed up to 2018. We compared all-cause dementia, Alzheimer’s disease (AD), and vascular dementia (VaD) incidence rates between proton pump inhibitor users and non-users by the Cox proportional hazard model. Results During 4,438,839 person-years of follow-up (median length of follow-up, 9.0 years), there were 2505 incident cases of all-cause dementia, including 932 cases of AD and 524 cases of VaD. The incident rate of all-cause dementia among proton pump inhibitor users was 1.06 events per 1000 person-years, compared with 0.51 events per 1000 person-years among non-users. After adjustment for multiple confounders and indications, the hazard ratios (HRs) of the proton pump inhibitor users were 1.20 (95% CI, 1.07–1.35) for incident all-cause dementia, 1.23 (95% CI, 1.02–1.49) for incident AD, and 1.32 (95% CI, 1.05–1.67) for incident VaD. In addition, the association between proton pump inhibitor use and all-cause dementia differed by APOE genotype (P for interaction = 0.048). Among APOE ε4 heterozygotes, the fully adjusted HR of proton pump inhibitor use was 1.46 (95% CI, 1.22–1.75) and 1.68 (95% CI, 1.36–2.07), especially for individuals aged 65 years and older. Conclusions The finding of this large population-based cohort study indicates that the use of proton pump inhibitors is associated with an increased risk of incident dementia, particularly among APOE ε4 heterozygotes.
first_indexed 2024-04-11T12:21:35Z
format Article
id doaj.art-87a2aaa057314bd4b04e1752e1d33648
institution Directory Open Access Journal
issn 1741-7015
language English
last_indexed 2024-04-11T12:21:35Z
publishDate 2022-09-01
publisher BMC
record_format Article
series BMC Medicine
spelling doaj.art-87a2aaa057314bd4b04e1752e1d336482022-12-22T04:24:05ZengBMCBMC Medicine1741-70152022-09-0120111110.1186/s12916-022-02478-yRegular proton pump inhibitor use and incident dementia: population-based cohort studyPeidong Zhang0Zhihao Li1Peiliang Chen2Ao Zhang3Yu Zeng4Xiru Zhang5Qingmei Huang6Dan Liu7Songtao Qi8Chen Mao9Department of Epidemiology, School of Public Health, Southern Medical UniversityDepartment of Epidemiology, School of Public Health, Southern Medical UniversityDepartment of Epidemiology, School of Public Health, Southern Medical UniversityState Key Laboratory of Molecular Neuroscience and Center of Systems Biology and Human Health, Division of Life Science, Hong Kong University of Science and TechnologyGuangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Department of Cell Biology, School of Basic Medical Sciences, Southern Medical UniversityDepartment of Epidemiology, School of Public Health, Southern Medical UniversityDepartment of Epidemiology, School of Public Health, Southern Medical UniversityDepartment of Epidemiology, School of Public Health, Southern Medical UniversityDepartment of Neurosurgery, Nanfang Hospital, Southern Medical UniversityDepartment of Epidemiology, School of Public Health, Southern Medical UniversityAbstract Background To examine the association between regular use of proton pump inhibitors and the risk of incident dementia, including dementia subtypes, and whether the association differs between APOE genotypes. Methods Based on a prospective analysis of data from the UK Biobank, 501,002 individuals (female, 54.4%) aged between 40 and 70 years, who had no prevalent dementia at baseline, were enrolled between 2006 and 2010 and followed up to 2018. We compared all-cause dementia, Alzheimer’s disease (AD), and vascular dementia (VaD) incidence rates between proton pump inhibitor users and non-users by the Cox proportional hazard model. Results During 4,438,839 person-years of follow-up (median length of follow-up, 9.0 years), there were 2505 incident cases of all-cause dementia, including 932 cases of AD and 524 cases of VaD. The incident rate of all-cause dementia among proton pump inhibitor users was 1.06 events per 1000 person-years, compared with 0.51 events per 1000 person-years among non-users. After adjustment for multiple confounders and indications, the hazard ratios (HRs) of the proton pump inhibitor users were 1.20 (95% CI, 1.07–1.35) for incident all-cause dementia, 1.23 (95% CI, 1.02–1.49) for incident AD, and 1.32 (95% CI, 1.05–1.67) for incident VaD. In addition, the association between proton pump inhibitor use and all-cause dementia differed by APOE genotype (P for interaction = 0.048). Among APOE ε4 heterozygotes, the fully adjusted HR of proton pump inhibitor use was 1.46 (95% CI, 1.22–1.75) and 1.68 (95% CI, 1.36–2.07), especially for individuals aged 65 years and older. Conclusions The finding of this large population-based cohort study indicates that the use of proton pump inhibitors is associated with an increased risk of incident dementia, particularly among APOE ε4 heterozygotes.https://doi.org/10.1186/s12916-022-02478-yProton pump inhibitorsDementiaAlzheimer’s diseaseAPOEAmyloid-β
spellingShingle Peidong Zhang
Zhihao Li
Peiliang Chen
Ao Zhang
Yu Zeng
Xiru Zhang
Qingmei Huang
Dan Liu
Songtao Qi
Chen Mao
Regular proton pump inhibitor use and incident dementia: population-based cohort study
BMC Medicine
Proton pump inhibitors
Dementia
Alzheimer’s disease
APOE
Amyloid-β
title Regular proton pump inhibitor use and incident dementia: population-based cohort study
title_full Regular proton pump inhibitor use and incident dementia: population-based cohort study
title_fullStr Regular proton pump inhibitor use and incident dementia: population-based cohort study
title_full_unstemmed Regular proton pump inhibitor use and incident dementia: population-based cohort study
title_short Regular proton pump inhibitor use and incident dementia: population-based cohort study
title_sort regular proton pump inhibitor use and incident dementia population based cohort study
topic Proton pump inhibitors
Dementia
Alzheimer’s disease
APOE
Amyloid-β
url https://doi.org/10.1186/s12916-022-02478-y
work_keys_str_mv AT peidongzhang regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT zhihaoli regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT peiliangchen regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT aozhang regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT yuzeng regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT xiruzhang regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT qingmeihuang regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT danliu regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT songtaoqi regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy
AT chenmao regularprotonpumpinhibitoruseandincidentdementiapopulationbasedcohortstudy